- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02786212
The Effects of Dexmedetomidine on Intestine and Other Organ Damages After Cardiac Surgeries
Cardiac surgery with cardiopulmonary bypass (CPB) provokes a systemic inflammatory response that can often lead to dysfunction of major organs. Activation of the contact system, endotoxemia, surgical trauma, and ischemic reperfusion injury are all possible triggers of inflammation. Previous studies demonstrated that pro-inflammatory cytokines play an important role during this process. However, very little is known about the susceptibility of the splanchnic organs to ischemic reperfusion injury. Although the incidence of intestinal complications reported to be low, the in-hospital mortality in these patients was high at 15% to 63%.
Dexmedetomidine, a highly selective α2-adrenergic agonist, can reduce the consumption of other sedative and antinociceptive drugs and provide sufficient sedative effects with minimal respiratory side effects. In addition, dexmedetomidine gradually has gained popularity in the field of critical care. Preemptive administration of dexmedetomidine has shown to be protective against inflammation, intestinal, renal, and myocardial injuries in animal and human studies. Dexmedetomidine is also used as an anesthetic adjuvant during surgery to offer good perioperative hemodynamic stability and an intraoperative anesthetic-sparing effect. Perioperative use of dexmedetomidine can reduce intestinal and hepatic injury after hepatectomy with inflow occlusion under general anesthesia. However, whether or not it can exert protective effects on the above-mentioned organs, especially intestine, after cardiac surgery remains unclear. The aim of this study is to evaluate the effects of dexmedetomidine on intestinal, hepatic, and other organ injury in patients receiving cardiac surgery with CPB.
In this double-blinded randomized controlled study, serum diamine oxidase activity, which is a sensitive and specific marker for the detection of intestinal injury, is taken as the primary endpoint. Other parameters reflecting the functions of liver (AST/ALT), lung (lung injury score and CC-16), kidney (BUN/Cre), and heart (CK-MB/Troponin T), the biomarker of endothelial injury (endocan) will also be determined. Besides, microcirculation parameters measured with Cytocam® and near-infrared spectroscopy (NIRS) will be used to estimate the protective effect of dexmedetomidine on microcirculation. The variables will be collected perioperatively and will be followed up for 3 days after the surgery. Clinical outcome parameters will be followed up for 3 months after the surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Po-Yuan Shih, MD
- Phone Number: 62158 886-2-23123456
- Email: shih.poyuan@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Po-Yuan Shih, MD
- Phone Number: 62158 886-2-23123456
- Email: shih.poyuan@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-emergent cardiac surgery with cardiopulmonary bypass
Exclusion Criteria:
- left ventricle ejection fraction < 40%
- acute myocardial infarction within 3 months
- angina within 48 hours before surgery
- COPD
- previous history of inflammatory bowel disease
- diarrhea within 7 days before surgery
- previous cardiac surgery
- receiving non-pharmacological cardiac supportive management
- previous pulmonary embolism
- previous deep vein thrombosis
- allergic to dexmedetomidine
- refractory bradycardia (HR < 60/min )
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dexmedetomidine
Patients receiving intraoperative dexmedetomidine infusion.
Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
|
|
Placebo Comparator: control
control group, receiving same volume of normal saline infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
diamine oxidase concentration
Time Frame: 1 hours after surgery
|
1 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
diamine oxidase concentration
Time Frame: 24 hours and 48 hours after surgery
|
24 hours and 48 hours after surgery
|
endocam concentration
Time Frame: 1 hours, 24 hours, and 48 hours after surgery
|
1 hours, 24 hours, and 48 hours after surgery
|
CC-16 concentration
Time Frame: 1 hours, 24 hours, and 48 hours after surgery
|
1 hours, 24 hours, and 48 hours after surgery
|
cerebral tissue oxygen saturation (StO2) measured by NIRS
Time Frame: 1 hours, 24 hours, and 48 hours after surgery
|
1 hours, 24 hours, and 48 hours after surgery
|
diamine oxidase concentration
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
endocam concentration
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
CC-16 concentration
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
diamine oxidase concentration
Time Frame: 1 hour after start of cardiopulmonary bypass
|
1 hour after start of cardiopulmonary bypass
|
endocam concentration
Time Frame: 1 hour after start of cardiopulmonary bypass
|
1 hour after start of cardiopulmonary bypass
|
CC-16 concentration
Time Frame: 1 hour after start of cardiopulmonary bypass
|
1 hour after start of cardiopulmonary bypass
|
cerebral tissue oxygen saturation (StO2) measured by NIRS
Time Frame: 1 hour after start of cardiopulmonary bypass
|
1 hour after start of cardiopulmonary bypass
|
diamine oxidase concentration
Time Frame: 10 minutes after the end of cardiopulmonary bypass
|
10 minutes after the end of cardiopulmonary bypass
|
Endocam concentration
Time Frame: 10 minutes after the end of cardiopulmonary bypass
|
10 minutes after the end of cardiopulmonary bypass
|
CC-16 concentration
Time Frame: 10 minutes after the end of cardiopulmonary bypass
|
10 minutes after the end of cardiopulmonary bypass
|
cerebral tissue oxygen saturation (StO2) measured by NIRS
Time Frame: 10 minutes after the end of cardiopulmonary bypass
|
10 minutes after the end of cardiopulmonary bypass
|
cerebral tissue oxygen saturation (StO2) measured by NIRS
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
perfused small vessel density
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
proportion of perfused small vessels
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
microvascular flow index
Time Frame: 10 minutes before anesthetic induction
|
10 minutes before anesthetic induction
|
perfused small vessel density
Time Frame: 1 hours after surgery
|
1 hours after surgery
|
proportion of perfused small vessels
Time Frame: 1 hours after surgery
|
1 hours after surgery
|
microvascular flow index
Time Frame: 1 hours after surgery
|
1 hours after surgery
|
perfused small vessel density
Time Frame: 24 hours after surgery
|
24 hours after surgery
|
proportion of perfused small vessels
Time Frame: 24 hours after surgery
|
24 hours after surgery
|
microvascular flow index
Time Frame: 24 hours after surgery
|
24 hours after surgery
|
perfused small vessel density
Time Frame: 48 hours after surgery
|
48 hours after surgery
|
proportion of perfused small vessels
Time Frame: 48 hours after surgery
|
48 hours after surgery
|
microvascular flow index
Time Frame: 48 hours after surgery
|
48 hours after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Po-Yuan Shih, MD, Department of Anesthesiology, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 201512224MINB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Surgical Procedure
-
Nantes University HospitalRecruitingCardiac Surgical ProcedureFrance
-
University Hospital Hradec KraloveCompletedCardiac Surgical ProcedureCzechia
-
Triemli HospitalCompletedCardiac Surgical Procedure | Diagnostic Techniques and Procedures
-
University of Texas Southwestern Medical CenterThe University of Texas Health Science Center, Houston; University of Alabama... and other collaboratorsCompletedSurgical Procedure, Unspecified | Surgical SimulationUnited States
-
3MCompletedSurgical Procedure, Unspecified | Surgical Skin PreparationRomania
-
Zealand University HospitalRecruiting
-
Hospital del MarRecruitingSurgical Procedure, UnspecifiedSpain
-
LifeBridge HealthRecruitingSurgical Procedure, UnspecifiedUnited States
-
University Hospital of SplitCompletedSurgical Procedure, UnspecifiedCroatia
-
Queen Mary Hospital, Hong KongCompleted
Clinical Trials on Dexmedetomidine
-
Cairo UniversityUnknownSpinal Anesthesia DurationEgypt
-
Guangzhou Women and Children's Medical CenterCompletedAmbulatory Surgical ProceduresChina
-
The First Affiliated Hospital with Nanjing Medical...CompletedPostoperative Pain | Breast Feeding | Analgesia ObstetricalChina
-
Seoul National University Bundang HospitalCompleted
-
Guangzhou General Hospital of Guangzhou Military...CompletedPharmacodynamic InteractionChina
-
University Hospital DubravaRecruitingAortic Valve Stenosis | Systemic Inflammatory ResponseCroatia
-
Guangzhou General Hospital of Guangzhou Military...Completed
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownArteriovenous MalformationChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownCombined Spinal-epidural AnesthesiaChina
-
Eye & ENT Hospital of Fudan UniversityCompletedAgitated; State, Acute Reaction to StressChina